Key points
- Epitalon is a synthetic tetrapeptide (AEDG) designed from the amino-acid composition of epithalamin, a bovine pineal gland extract [12].
- In human fetal fibroblasts it was associated with expression of the telomerase catalytic subunit, telomere elongation and 10 additional cell divisions [2][3].
- In SHR mice it did not change mean life span. It was associated with a 13.3% increase in the life span of the last 10% of survivors and a 12.3% increase in maximum life span [4].
- The lower-mortality data in older adults come mainly from epithalamin (the extract), not from synthetic epitalon [7][8].
- An independent British group also observed telomere elongation in normal cells in vitro in 2025, while FDA identified no clinical safety studies in humans [10][13].
US status (October 2026): Not FDA-approved, with no lawful compounding pathway as of September 26, 2026. MDside providers do not prescribe it. Epitalon status page.
Epitalon is one synthetic peptide from a much older research program
Epitalon (also epithalon or AEDG) is a synthetic tetrapeptide, Ala-Glu-Asp-Gly. It was designed from the amino-acid composition of epithalamin, a peptide complex extracted from the bovine pineal gland, and was later identified in that same mixture [12]. It comes from the St. Petersburg Institute of Bioregulation and Gerontology, Professor Vladimir Khavinson’s group [8].
The program is long. As early as 1982 the group reported longer life span and lower tumor incidence in C3H/Sn mice treated with polypeptide factors from the thymus and epiphysis [1]. A 2025 Polish review summarizes the last 25 years of in-vitro, in-vivo and in-silico epitalon studies [12]. For a comparison with MOTS-c, NAD+ and SS-31, see Epitalon, MOTS-c, NAD+ and SS-31.
The telomere hypothesis comes from cell culture
The work that made epitalon famous was published in 2003. In telomerase-negative human fetal fibroblast cultures, adding the peptide was associated with expression of the enzyme’s catalytic subunit, its enzymatic activity and telomere elongation [2].
A year later the same group used pulmonary fibroblasts from a 24-week fetus, which lost the ability to divide at passage 34. With epitalon, telomeres lengthened to a size comparable to early passages and the cells made 10 additional divisions (44 passages) and kept dividing. The authors described this as overcoming the Hayflick limit [3].
- +10: additional divisions in treated human fibroblasts [3]
- 12.3%: increase in maximum life span in SHR mice [4]
- 7 to 5: FDA advisory committee vote in favor of epitalon, 1 abstention [14]
Aged mice and monkeys show modest, specific effects
The most cited mouse study included 54 female mice per group, treated from 3 months of age until natural death on 5 consecutive days each month. Epitalon did not change food intake, body weight or mean life span. It was associated with slower age-related loss of estrous function, 17.1% fewer chromosome aberrations in bone marrow, a 13.3% increase in the life span of the last 10% of survivors and a 12.3% increase in maximum life span. Total spontaneous tumor incidence did not change. Leukemia was 6.0-fold less frequent. The authors concluded that the data suggest geroprotective activity and safety of long-term administration in mice [4].
In rhesus monkeys aged 20 to 27 years, epitalon was associated with lower basal glucose and insulin, higher nocturnal melatonin and a better response to a glucose load. It had no effect in young animals [5]. That pattern, acting on what is disturbed and leaving what is normal alone, reappears in the human melatonin study [6].
The human mortality data belong to the extract
In healthy older adults, a course of epithalamin was associated with higher nocturnal melatonin in those with reduced pineal function. In those with normal function the concentration tended to fall [6]. The authors interpret this as modulation rather than simple stimulation.
The mortality data are the most striking. In a 12-year randomized study of older adults with coronary disease and accelerated cardiovascular aging, the epithalamin group had 28% fewer deaths and half the cardiovascular mortality of the control group [7]. In another cohort of 266 older people followed for 6 to 8 years, mortality was 1.6 to 1.8 times lower with epithalamin [8]. When a patient cites these numbers, the point to make is simple: these data are for epithalamin, the extract, not synthetic epitalon.
For epitalon itself, FDA found three human studies: two with sublingual administration in night-shift workers and one with parabulbar injection in retinitis pigmentosa [13]. In the latter, Khavinson’s group reported a positive clinical effect in 90% of cases [9]. Epitalon received an orphan drug designation for retinitis pigmentosa in 2010, withdrawn in 2016 [13].
Independent work started in 2025
In 2025 a team at Brunel University London, with no declared conflicts of interest, treated normal epithelial cells and fibroblasts and two breast cancer lines (21NT and BT474). In normal cells it observed dose-dependent telomere elongation through upregulation of hTERT mRNA and telomerase activity. In the tumor lines, elongation occurred through a different route, the ALT mechanism (alternative lengthening of telomeres) [10].
The same year, an Italian group working with St. Petersburg found that, in retinal pigment epithelial cells injured by high glucose, epitalon restored in-vitro wound healing and inhibited epithelial-mesenchymal transition and fibrosis [11]. The Warsaw review adds that, despite the volume of biological data, it remains unclear whether telomerase and melatonin are its only mechanisms, and that physicochemical and structural studies are scarce [12].
Where the evidence ends
The first limit is one of origin, and it does not diminish the work. Of the nine references in this article published before 2025, all have Khavinson or Anisimov as an author [1][2][3][4][5][6][7][8][9], and several appeared in Russian journals or their translations. Independent replication is only beginning [10].
The second is regulatory. In its 2026 briefing document FDA found no pharmacokinetic data and wrote that it “has not identified clinical studies assessing the safety of epitalon-related BDSs administered in humans”. Its adverse-event database search through December 8, 2025 retrieved no reports. On mechanistic grounds, the agency noted that epitalon “has the potential to be carcinogenic”, and that the mouse studies, with a fixed dose, females only and short exposure, are not enough to rule this out [13]. The ALT finding in tumor cells is consistent with that caution [10].
Even so, the advisory committee voted 7 to 5, with one abstention, to add epitalon to the compounding list for insomnia, overriding FDA staff [14]. The vote is nonbinding. The documents are covered in What FDA really said about peptides, and the legal background in are peptides legal.
Epitalon and epithalamin are not interchangeable. Epithalamin is a pineal extract with many peptides. Epitalon is a single synthetic tetrapeptide. The human mortality results belong to epithalamin [7][8]. The cellular telomerase results belong to epitalon [2][10].
A balanced reading. For: a research program of more than 40 years [1], a coherent hypothesis whose telomerase effect a British university also observed in normal cells in vitro [10], data in aged monkeys [5] and no adverse-event reports in the FDA database [13]. Against: nearly all the evidence comes from one group, and independent controlled human trials are lacking [12][13]. If patients bring you epitalon bought online, it is a “research use only” product with no US pathway, which we explain in research-use-only peptides.
References
- Anisimov VN, et al. [Increase of the life span and decrease in the tumor incidence in C3H/Sn mice as affected by thymus and epiphysis polypeptide factors]. Dokl Akad Nauk SSSR. 1982;263(3):742-5. PMID 6978806. Link
- Khavinson VKh, Bondarev IE, Butyugov AA. Epithalon peptide induces telomerase activity and telomere elongation in human somatic cells. Bull Exp Biol Med. 2003;135(6):590-2. PMID 12937682. Link
- Khavinson VKh, et al. Peptide promotes overcoming of the division limit in human somatic cell. Bull Exp Biol Med. 2004;137(5):503-6. PMID 15455129. Link
- Anisimov VN, et al. Effect of Epitalon on biomarkers of aging, life span and spontaneous tumor incidence in female Swiss-derived SHR mice. Biogerontology. 2003;4(4):193-202. PMID 14501183. Link
- Goncharova ND, et al. Pineal peptides restore the age-related disturbances in hormonal functions of the pineal gland and the pancreas. Exp Gerontol. 2005;40(1-2):51-7. PMID 15664732. Link
- Korkushko OV, et al. Effect of peptide preparation epithalamin on circadian rhythm of epiphyseal melatonin-producing function in elderly people. Bull Exp Biol Med. 2004;137(4):389-91. PMID 15452611. Link
- Korkushko OV, et al. Geroprotective effect of epithalamine (pineal gland peptide preparation) in elderly subjects with accelerated aging. Bull Exp Biol Med. 2006;142(3):356-9. PMID 17426848. Link
- Khavinson VKh, Morozov VG. Peptides of pineal gland and thymus prolong human life. Neuro Endocrinol Lett. 2003;24(3-4):233-40. PMID 14523363. Link
- Khavinson V, et al. Pineal-regulating tetrapeptide epitalon improves eye retina condition in retinitis pigmentosa. Neuro Endocrinol Lett. 2002;23(4):365-8. PMID 12195242. Link
- Al-Dulaimi S, et al. Epitalon increases telomere length in human cell lines through telomerase upregulation or ALT activity. Biogerontology. 2025;26(5):178. PMID 40908429. Link
- Gatta M, et al. The antioxidant tetrapeptide Epitalon enhances delayed wound healing in an in vitro model of diabetic retinopathy. Stem Cell Rev Rep. 2025;21(6):1822-1834. PMID 40493162. Link
- Araj SK, et al. Overview of Epitalon: highly bioactive pineal tetrapeptide with promising properties. Int J Mol Sci. 2025;26(6):2691. PMID 40141333. Link
- U.S. Food and Drug Administration. PCAC July 2026 briefing document: Epitalon. Link
- Eglovitch JS. FDA advisory committee backs two more peptides, rejects one for compounding list. RAPS. 24 July 2026. Link
This is general information, not medical or legal advice. Rules vary by state and change. Confirm your own facts with counsel.